| Updated:
Johnson & Johnson to start human testing on Ebola vaccine
US PHARMA giant Johnson & Johnson announced today that it would begin human trials of its Ebola vaccine in January.
The company said it would spend $200m (£124m) on speeding up its research programme, and begin testing in America, Africa and Europe early next year.
The vaccine combines a formula from one of its subsidiaries, Janssen, with one from Danish pharma firm Bavarian Nordic.
It targets the Zaire strain of the disease, currently affecting countries in West Africa, and has “shown promising results”, said the company.